There are over 44 million suffering from Alzheimer's Disease, and two big Pharma companies just teamed up to find a cure for the disease. Eli Lilly and Astra Zeneca joined forces to develop a drug that would possibly bring in $5 billion in revenue, but only has a 9% chance of making it to the market.
According to the Wall Street Journal, in this partnership, the two companies are sharing the risk of development, clinical trials, commercialization costs and any future revenue. The BACE Inhibitor drug in development shows promise by stopping the beta amyloids- or protein fragments - that are associated with the development of the disease.
This Thursday, we're teaming up with PRA Health Sciences to see what other developments are in the works in the Pharmaceutical landscape in the web seminar Drug Development in Alzheimer’s Disease: Reasons to Remain Optimistic. Register to join speaker Frederick T. Lewis, D.O., Vice President Neurosciences, Scientific Affairs at PRA Health Sciences at 11:00AM ET. Register here and mention priority code P2000W1BLOG.
What do you see as the biggest benefits of partnering with another company to share the risk of a treatment that could save so many people who are suffering from the disease?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to firstname.lastname@example.org.